論文 - 詳細
| RRC ID | 44528 |
|---|---|
| 著者 | Okamoto K, Kodama K, Takase K, Sugi NH, Yamamoto Y, Iwata M, Tsuruoka A. |
| タイトル | Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. |
| ジャーナル | Cancer Lett |
| Abstract |
RET gene fusions are recurrent oncogenes identified in thyroid and lung carcinomas. Lenvatinib is a multi-tyrosine kinase inhibitor currently under evaluation in several clinical trials. Here we evaluated lenvatinib in RET gene fusion-driven preclinical models. In cellular assays, lenvatinib inhibited auto-phosphorylation of KIF5B-RET, CCDC6-RET, and NcoA4-RET. Lenvatinib suppressed the growth of CCDC6-RET human thyroid and lung cancer cell lines, and as well, suppressed anchorage-independent growth and tumorigenicity of RET gene fusion-transformed NIH3T3 cells. These results demonstrate that lenvatinib can exert antitumor activity against RET gene fusion-driven tumor models by inhibiting oncogenic RET gene fusion signaling. |
| 巻・号 | 340(1) |
| ページ | 97-103 |
| 公開日 | 2013-10-28 |
| DOI | 10.1016/j.canlet.2013.07.007 |
| PII | S0304-3835(13)00512-0 |
| PMID | 23856031 |
| MeSH | Animals Antineoplastic Agents / pharmacology* Cell Line, Tumor Cell Transformation, Neoplastic / drug effects Cell Transformation, Neoplastic / genetics Cytoskeletal Proteins / genetics Cytoskeletal Proteins / metabolism Drug Screening Assays, Antitumor Female Humans Mice Mice, Inbred BALB C Mice, Nude NIH 3T3 Cells Neoplasm Transplantation Neoplasms / drug therapy* Neoplasms / enzymology Neoplasms / genetics Oncogene Proteins, Fusion / antagonists & inhibitors* Oncogene Proteins, Fusion / genetics Oncogene Proteins, Fusion / metabolism Phenylurea Compounds / pharmacology* Protein Kinase Inhibitors / pharmacology Proto-Oncogene Proteins c-ret / antagonists & inhibitors* Proto-Oncogene Proteins c-ret / genetics Proto-Oncogene Proteins c-ret / metabolism Quinolines / pharmacology* Signal Transduction |
| IF | 7.36 |
| 引用数 | 126 |
| WOS 分野 | ONCOLOGY |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 8 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | LC-2/ad(RCB0440) |